Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00313
|
|||||
Drug Name |
Cefadroxil
|
|||||
Synonyms |
(6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid; BL-S 578; BL-S578; CDX; Cefadroxil (JP15); Cefadroxil anhydrous; Cefadroxilo; Cefadroxilo [INN-Spanish]; Cefadroxilum; Cefadroxilum [INN-Latin]; Cephadroxil; Curisafe (TN); D-Cefadroxil; MJF-11567-3; S 578; S-578; Sumacef; Sumacef (TN)
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Gram-positive & negative bacteria infections [ICD11: 1A00-1H0Z] | Approved | [1] | |||
Therapeutic Class |
Antibiotics
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C16H17N3O5S
|
|||||
Canonical SMILES |
CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O
|
|||||
InChI |
InChI=1S/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1
|
|||||
InChIKey |
BOEGTKLJZSQCCD-UEKVPHQBSA-N
|
|||||
CAS Number |
CAS 66592-87-8
|
|||||
Pharmaceutical Properties | Molecular Weight | 363.4 | Topological Polar Surface Area | 158 | ||
Heavy Atom Count | 25 | Rotatable Bond Count | 4 | |||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 7 | |||
XLogP |
-2.1
|
|||||
PubChem CID | ||||||
PubChem SID |
103620148
, 103914339
, 104133801
, 104354273
, 10990583
, 11335584
, 11360823
, 11362958
, 11365520
, 11368082
, 11373871
, 11376244
, 11461795
, 11466462
, 11467582
, 11483750
, 11486123
, 11487903
, 11492081
, 11493918
, 121363085
, 124766005
, 14852631
, 16050996
, 24892921
, 25622160
, 34712894
, 46509128
, 47440185
, 47515253
, 47515254
, 47959665
, 48035040
, 48334422
, 48415709
, 49699087
, 50124273
, 57654040
, 75439952
, 7847323
, 7978892
, 8149235
, 85279381
, 87322627
, 90451718
, 9095
, 92125414
, 93576133
, 93576712
, 99301497
|
|||||
ChEBI ID |
CHEBI:3479
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [2] | |
MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | ||
MRP3 | Transporter Info | Multidrug resistance-associated protein 3 | Substrate | [2] | ||
MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [2] | ||
PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [3] | ||
PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [4] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | MRP1 | Transporter Info | Km = 3.9 microM | Human embryonic kidney cells (HEK293)-MRP1 | [2] | |
MRP3 | Transporter Info | Km = 2.5 microM | Spodoptera frugiperda 21 (Sf21) cells-MRP3 | [2] | ||
MRP4 | Transporter Info | Km = 0.25 microM | Spodoptera frugiperda 21 (Sf21) cells-MRP4 | [2] | ||
PEPT1 | Transporter Info | Km = 7.97 microM | Human cervical cancer cell line (Hela)-PEPT1 | [3] | ||
PEPT2 | Transporter Info | Km = 150.8 microM | In vivo model (human) | [4] | ||
References | ||||||
1 | Cefadroxil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21. | |||||
3 | High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9. | |||||
4 | Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.